Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 11Prostatic Neoplasms 7Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 4Triple Negative Breast Neoplasms 3Endometrial Neoplasms 3Small Cell Lung Carcinoma 2Fallopian Tube Neoplasms 2mCRPC 1Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Pheochromocytoma 1Pathologic Complete Response 1Paraganglioma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Gemcitabine 113130-nm albumin-bound paclitaxel 64Albumin-Bound Paclitaxel 43Fluorouracil 37Magnetic Resonance Spectroscopy 35pembrolizumab 34Irinotecan 34Taxes 33Specimen Handling 33Leucovorin 33Oxaliplatin 31Biopsy 22Cyclophosphamide 21Nivolumab 18fludarabine 16Radiosurgery 16Cisplatin 16Drug Therapy 15Capecitabine 12folfirinox 11durvalumab 11Radiotherapy 11irinotecan sucrosofate 10Ipilimumab 10Cetuximab 10Carboplatin 10Blood Specimen Collection 10olaparib 9Standard of Care 9dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × talazoparib × 1 year × Clear all
NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

Phase 2 Recruiting
36 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡